Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
Previous Symbol
CUSIPN/A
Phone415-818-1001
Debt
Debt-to-Equity RatioN/A
Current Ratio14.83
Quick Ratio14.83
Price-To-Earnings
Trailing P/E Ratio-6.69
Forward P/E Ratio-6.76
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.38) per share
Price / Book-4.22
Profitability
EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-37.47%
Miscellaneous
Employees152
Outstanding Shares42,690,000
Market Cap$1.00 billion
OptionableOptionable
Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.09. During the same quarter in the previous year, the company posted ($0.88) earnings per share. View Audentes Therapeutics' Earnings History.
When is Audentes Therapeutics' next earnings date?
What price target have analysts set for BOLD?
11 equities research analysts have issued 12 month price objectives for Audentes Therapeutics' stock. Their forecasts range from $20.00 to $49.00. On average, they expect Audentes Therapeutics' share price to reach $35.8750 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.
What is the consensus analysts' recommendation for Audentes Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.
What are Wall Street analysts saying about Audentes Therapeutics stock?
Here are some recent quotes from research analysts about Audentes Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our Buy rating and $33 price target on shares of Audentes are based on sum-of-the-parts analysis of the company’s pipeline. We value the XLMTM commercial opportunity at $17/share, and CN at $16/share, each of which are based on a 5x P/ S multiple on peak sales of roughly $579M (XLMTM peak sales of about $300M and CN peak sales of approximately $279M in FY2025), discounted at 10% over a 7-year period. Our 5x P/S multiple is below the lower end of historic M&A within the sector (typically in the range of 7-9x)." (11/7/2018)
- 2. Mizuho analysts commented, "We do not see earnings as the best indicator of value for an early-stage biotech. Importantly, progress continues to be highly encouraging on the AT-132 program. Audentes is expected to meet with the FDA and EMA in 4Q18 to discuss development plans and a potential registrational pathway for AT132. An update is expected in 1Q19, which could be an important catalyst. Two other pipeline products; in Criggler-Najjar and Pompe disease need further work (more below). Finally, a new program targeting a large neuromuscular disease remains to be disclosed, which could add upside to the shares as well." (11/7/2018)
- 3. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (8/9/2018)
- 4. Chardan Capital analysts commented, "We initiate coverage on Neutral rating (PT$35): While we see the company’s initial phase I/II results with AAV-based gene therapies (GT) as promising, we see more constrained market opportunities due to small patient populations. Audentes has developed 4 assets to target rare/ultra-rare diseases of the liver, heart, or skeletal muscle. The lead product candidate, AT132, is an AAV8-based GT being tested in the phase I/II ASPIRO trial (NCT03199469) as a treatment for X-linked myotubular myopathy (XLMTM). The 2nd clinical stage asset is AT342, an AAV8-based GT in the phase I/II VALENS trial (NCT03223194) for Crigler-Najjar syndrome (CN). 2 additional products, AT982 for Pompe disease and AT307 for CASQ2-CPVT, are in preclinical development." (6/25/2018)
Has Audentes Therapeutics been receiving favorable news coverage?
News articles about BOLD stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Are investors shorting Audentes Therapeutics?
Audentes Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,063,010 shares, an increase of 76.3% from the September 28th total of 1,737,349 shares. Based on an average daily volume of 928,837 shares, the short-interest ratio is currently 3.3 days. Currently, 9.6% of the company's stock are short sold. View Audentes Therapeutics' Current Options Chain.
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX) and Spark Therapeutics (ONCE).
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Mr. Matthew R. Patterson, Co-Founder, CEO & Director (Age 46)
- Ms. Natalie C. Holles, Pres & COO (Age 45)
- Mr. Thomas P. Soloway, Sr. VP & CFO (Age 51)
- Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 55)
- Mr. Andrew H. Chang, Director of Investor Relations
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Audentes Therapeutics' major shareholders?
Audentes Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (10.44%), BlackRock Inc. (6.88%), Redmile Group LLC (5.25%), Partner Fund Management L.P. (3.64%), Jennison Associates LLC (2.76%) and Victory Capital Management Inc. (2.04%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.
Which major investors are selling Audentes Therapeutics stock?
BOLD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Virtus ETF Advisers LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.
Which major investors are buying Audentes Therapeutics stock?
BOLD stock was bought by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Nexthera Capital LP, Alliancebernstein L.P., Pictet Asset Management Ltd., Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Sphera Funds Management LTD. and BlackRock Inc.. View Insider Buying and Selling for Audentes Therapeutics.
How do I buy shares of Audentes Therapeutics?
Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of BOLD stock can currently be purchased for approximately $22.73.
How big of a company is Audentes Therapeutics?
Audentes Therapeutics has a market capitalization of $1.00 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.
What is Audentes Therapeutics' official website?
How can I contact Audentes Therapeutics?
Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]
MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
